Literature DB >> 26152426

Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).

Sheo B Singh1, David E Kaelin2, Peter T Meinke2, Jin Wu2, Lynn Miesel2, Christopher M Tan2, David B Olsen3, Armando Lagrutta3, Hideyuki Fukuda4, Ryuta Kishii4, Masaya Takei4, Tomoko Takeuchi4, Hisashi Takano4, Kohei Ohata4, Haruaki Kurasaki4, Akinori Nishimura4, Takeshi Shibata4, Yasumichi Fukuda5.   

Abstract

Oxabicyclooctane linked novel bacterial topoisomerase inhibitors (NBTIs) are new class of recently reported broad-spectrum antibacterial agents. They target bacterial DNA gyrase and topoisomerase IV and bind to a site different than quinolones. They show no cross-resistance to known antibiotics and provide opportunity to combat drug-resistant bacteria. A structure activity relationship of the C-2 substituted ether analogs of 1,5-naphthyridine oxabicyclooctane-linked NBTIs are described. Synthesis and antibacterial activities of a total of 63 analogs have been summarized representing alkyl, cyclo alkyl, fluoro alkyl, hydroxy alkyl, amino alkyl, and carboxyl alkyl ethers. All compounds were tested against three key strains each of Gram-positive and Gram-negative bacteria as well as for hERG binding activities. Many key compounds were also tested for the functional hERG activity. Six compounds were evaluated for efficacy in a murine bacteremia model of Staphylococcus aureus infection. Significant tolerance for the ether substitution (including polar groups such as amino and carboxyl) at C-2 was observed for S. aureus activity however the same was not true for Enterococcus faecium and Gram-negative strains. Reduced clogD generally showed reduced hERG activity and improved in vivo efficacy but was generally associated with decreased overall potency. One of the best compounds was hydroxy propyl ether (16), which mainly retained the potency, spectrum and in vivo efficacy of AM8085 associated with the decreased hERG activity and improved physical property.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibacterial; Bacterial topoisomerase inhibitors; Broad-spectrum; Gyrase inhibitors; ParC inhibitors

Mesh:

Substances:

Year:  2015        PMID: 26152426     DOI: 10.1016/j.bmcl.2015.06.061

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase.

Authors:  Christopher M Tan; Charles J Gill; Jin Wu; Nathalie Toussaint; Jingjun Yin; Takayuki Tsuchiya; Charles G Garlisi; David Kaelin; Peter T Meinke; Lynn Miesel; David B Olsen; Armando Lagrutta; Hideyuki Fukuda; Ryuta Kishii; Masaya Takei; Kouhei Oohata; Tomoko Takeuchi; Taku Shibue; Hisashi Takano; Akinori Nishimura; Yasumichi Fukuda; Sheo B Singh
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site.

Authors:  Sebastian Franco-Ulloa; Giuseppina La Sala; Gian Pietro Miscione; Marco De Vivo
Journal:  Int J Mol Sci       Date:  2018-02-03       Impact factor: 5.923

Review 3.  Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs).

Authors:  Anja Kolarič; Marko Anderluh; Nikola Minovski
Journal:  J Med Chem       Date:  2020-02-17       Impact factor: 7.446

Review 4.  Synthetic Strategies, Reactivity and Applications of 1,5-Naphthyridines.

Authors:  Maria Fuertes; Carme Masdeu; Endika Martin-Encinas; Asier Selas; Gloria Rubiales; Francisco Palacios; Concepcion Alonso
Journal:  Molecules       Date:  2020-07-16       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.